{"product_id":"ango-bcg-matrix","title":"(ANGO) AngioDynamics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis AngioDynamics, Inc. BCG Matrix helps you assess how the company’s products or business units fit into the Stars, Cash Cows, Question Marks, and Dogs framework for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before purchasing. Buy the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNanoKnife\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNanoKnife is AngioDynamics, Inc.'s irreversible electroporation platform for soft-tissue ablation in oncology, so it fits the fast-growing minimally invasive cancer-treatment space. AngioDynamics reported FY2025 net sales of about $306 million, and NanoKnife remains one of its clearest growth levers. If adoption keeps rising, it is the strongest Star candidate in the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolero\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSolero fits AngioDynamics, Inc. as a Star because its microwave and radiofrequency systems target solid tumor ablation, where image-guided oncology procedures still see steady demand. Clinical use is still widening, and each case can create recurring procedural volume for hospitals and interventional teams. In a growing niche, Solero has room to scale as ablation shifts toward less invasive cancer care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAuryon\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAuryon fits \"Stars\" in AngioDynamics, Inc.'s BCG Matrix because it targets peripheral atherectomy in a PAD market that still drives a high procedure load. PAD affects about 230 million adults worldwide, so demand is real, not niche. If AngioDynamics keeps gaining share in endovascular therapies, Auryon can stay a growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAlphaVac\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlphaVac fits the Stars side of AngioDynamics, Inc. BCG Matrix because it targets mechanical thrombectomy and clot removal, both tied to a fast-growing thrombus management market. In fiscal 2025, AngioDynamics reported net sales of about $300 million, so AlphaVac still needs steady clinical adoption and sales support to scale faster.\u003c\/p\u003e\n\u003cp\u003eIts value comes from use in high-need interventional cases, where faster clot removal can matter. The franchise can stay a Star only if physicians keep adopting it and AngioDynamics keeps backing training, data, and commercial reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMechanical thrombectomy drives growth\u003c\/li\u003e\n\u003cli\u003eThrombus care stays a high-demand niche\u003c\/li\u003e\n\u003cli\u003eFY2025 sales were about $300 million\u003c\/li\u003e\n\u003cli\u003eAdoption and sales support still matter\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEndovascular therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEndovascular therapies are AngioDynamics, Inc.'s clearest growth engine outside oncology ablation, led by thrombus management, atherectomy, and core peripheral products. These are procedure-driven categories, so demand tracks case volumes and new clinical adoption more than one-off purchases. Ongoing device upgrades and broader use in vascular labs keep this franchise in the \"Star\" zone.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThrombus management drives recurring procedure use\u003c\/li\u003e\n\u003cli\u003eAtherectomy benefits from new technique adoption\u003c\/li\u003e\n\u003cli\u003eCore peripheral products widen installed reach\u003c\/li\u003e\n\u003cli\u003eInnovation supports share in active markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAngioDynamics’ Star Products Are Driving Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNanoKnife, Solero, Auryon, and AlphaVac are AngioDynamics, Inc.'s clearest Stars because they sit in growing, procedure-driven markets and support the company’s FY2025 net sales of about $306 million. NanoKnife and Solero lead in oncology ablation, while Auryon and AlphaVac tap high-need vascular care. The key test is faster physician adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar product\u003c\/th\u003e\n\u003cth\u003eMarket signal\u003c\/th\u003e\n\u003cth\u003eFY2025 note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNanoKnife\u003c\/td\u003e\n\u003ctd\u003eOncology ablation\u003c\/td\u003e\n\u003ctd\u003eGrowth lever\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuryon\u003c\/td\u003e\n\u003ctd\u003ePAD treatment\u003c\/td\u003e\n\u003ctd\u003eProcedure demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlphaVac\u003c\/td\u003e\n\u003ctd\u003eThrombectomy\u003c\/td\u003e\n\u003ctd\u003eNeeds scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAngioDynamics BCG Matrix maps its businesses into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page AngioDynamics BCG Matrix to quickly spot winners, losers, and capital priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eShows the source trail behind AngioDynamics data, making the analysis more credible and easier to use in decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioFlo PICC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioFlo PICC is a mature vascular access brand, so it fits Cash Cows in AngioDynamics, Inc.’s BCG Matrix. PICCs are used for weeks to months in hospitals and infusion centers, and their established clinical role supports steady repeat demand and stable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioFlo Midline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn FY2025, AngioDynamics generated about $303 million in net sales, and BioFlo Midline sits in a mature inpatient category where routine vascular access demand stays steady.\u003c\/p\u003e\n\u003cp\u003eMidline catheters are standard hospital products, so utilization is recurring and less tied to new market buildout.\u003c\/p\u003e\n\u003cp\u003eThat makes BioFlo Midline a classic cash cow: limited growth spend, stable volume, and reliable cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioFlo Port\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioFlo Port is a mature implantable port in AngioDynamics, Inc.’s portfolio, used for chemotherapy and other repeat infusions. As a 2025-style Cash Cow, it sits in an established category that usually brings steady replacement demand, stable margins, and dependable cash flow. AngioDynamics, Inc.’s fiscal 2025 filings still showed the value of installed-base revenue in this franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVortex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVortex is an implantable port brand in AngioDynamics, Inc.'s vascular access line, and ports are a mature hospital category with steady replacement demand. That makes Vortex a cash-cow asset, not a heavy growth bet. AngioDynamics reported fiscal 2025 net sales of $304.9 million and gross margin of 52.4%, which supports cash generation over aggressive expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature, recurring hospital use\u003c\/li\u003e\n\u003cli\u003eLow-growth, cash-focused fit\u003c\/li\u003e\n\u003cli\u003eSupports portfolio profitability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDuraMax\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDuraMax sits in catheter-based vascular access, where hospitals rely on stable, repeat-use workflows. That makes it fit the BCG Cash Cow slot: low-growth, but able to keep generating cash because the clinical need is steady and the product is already embedded in routine care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCatheter-based vascular access\u003c\/li\u003e\n\u003cli\u003eStable hospital workflow use\u003c\/li\u003e\n\u003cli\u003eLow growth, cash-rich profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor AngioDynamics, Inc., DuraMax is more about harvesting margins than chasing rapid category growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAngioDynamics’ Cash Cows Deliver Steady, Margin-Backed Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioFlo PICC, BioFlo Midline, BioFlo Port, Vortex, and DuraMax are Cash Cows for AngioDynamics, Inc. because they sit in mature vascular access niches with recurring hospital use and limited growth spend. FY2025 net sales were about $303 million to $304.9 million, and gross margin was 52.4%, which supports steady cash generation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioFlo PICC\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003eRepeat demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioFlo Midline\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003eRoutine inpatient use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioFlo Port\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003eInstalled base revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVortex\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003eStable replacement demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDuraMax\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003eHarves t margins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAngioDynamics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the actual AngioDynamics, Inc. BCG Matrix document you’ll receive after purchase. The file is fully formatted and ready to use, with no demo pages or hidden content. What you see here is the same professional report delivered instantly after checkout. It’s designed for quick review, printing, or sharing with your team.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAngiographic catheters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAngioDynamics, Inc.’s angiographic catheters fit the Dogs box: they are standard interventional-lab tools with low differentiation, so price pressure stays intense. In a crowded catheter market that supports only modest growth, these products usually add little operating leverage. That is why they tend to trail higher-value lines in margin and return on capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuidewires\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuidewires are foundational interventional accessories, but they compete in a crowded field dominated by larger medtech suppliers. For AngioDynamics, Inc., this fits a Dogs profile: low growth, low relative share, and limited pricing power, which is why the line usually acts as a cash drain rather than a growth driver. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePercutaneous drainage catheters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePercutaneous drainage catheters sit in routine image-guided care, so demand is steady but not fast-growing. In AngioDynamics, Inc.'s BCG Matrix, that profile fits a weak \"Dog\" because the market is fragmented and pricing is commodity-like, with little scope for margin expansion. This makes it a low-priority line versus faster-growth, higher-return categories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCoaxial micro-introducer kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoaxial micro-introducer kits are a necessary access tool in AngioDynamics, Inc.'s portfolio, but they usually stay a low-growth \"Dog\" because they support procedure setup more than they drive demand. AngioDynamics reported fiscal 2025 results at the company level, but it did not break out revenue for this kit line, which points to limited standalone scale. The line is more likely to be maintained for clinical completeness than pushed for major expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUseful, but not a growth engine.\u003c\/li\u003e\n\u003cli\u003eSupports access and placement.\u003c\/li\u003e\n\u003cli\u003eLikely kept, not aggressively expanded.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIsoLoc and Alatus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIsoLoc and Alatus address narrow positioning and packing needs, so they fit a Dog in AngioDynamics, Inc.’s BCG Matrix. AngioDynamics reported fiscal 2025 revenue near $307 million, and these products do not look like scale drivers versus its bigger med-tech focus. Small niche demand and slow category growth keep their cash potential limited.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNiche use, not broad demand\u003c\/li\u003e\n\u003cli\u003eSmall scale limits growth\u003c\/li\u003e\n\u003cli\u003eBest viewed as a Dog\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAngioDynamics Dogs: Small, Slow, and Best Kept for Coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAngioDynamics, Inc.’s Dogs are low-share, low-growth lines with weak pricing power, so they add little profit lift. In fiscal 2025, company revenue was about $307 million, but these niche accessories did not show the scale needed to change the mix. They are usually kept for coverage and completeness, not expanded.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eDogs fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShare\u003c\/td\u003e\n\u003ctd\u003eSmall\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRole\u003c\/td\u003e\n\u003ctd\u003eMaintain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlphaVac PE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlphaVac PE sits in a growing pulmonary embolism market, and PE affects about 900,000 people a year in the U.S. AngioDynamics is still building broader share, so AlphaVac is a question mark, not a cash cow. It needs more investment and adoption to become a clear market leader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAuryon CLI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAuryon CLI sits in a growing niche: critical limb ischemia and complex PAD still need better endovascular tools, so demand can rise with more physician adoption. In AngioDynamics, Inc. FY2025 results, the product still needs clear share gains and a larger installed base to move out of Question Mark territory. If adoption broadens, it can capture more of this high-need market, but today its growth is still not proven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNanoKnife pancreas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNanoKnife pancreas fits the Question Mark box: pancreatic cancer still has about a 13% 5-year survival rate, so the unmet need is high. AngioDynamics, Inc. is chasing that need, but adoption is still limited and must broaden beyond early users. The clinical upside is real, yet FY2025 demand is still in build mode rather than at scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSolero liver tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSolero fits a growing liver tumor ablation market, and that demand supports its BCG Question Mark status. AngioDynamics reported FY2025 net sales of about $286 million, but Solero still needs sharper share gains before it can look like a Star.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowing liver ablation demand helps Solero.\u003c\/li\u003e\n\u003cli\u003eMarket penetration still looks too thin.\u003c\/li\u003e\n\u003cli\u003eShare gains matter more than market growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBioSentry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioSentry fits the Question Mark in AngioDynamics, Inc.'s BCG Matrix: it solves a real clinical need as a tract sealant, but the market is narrow and the product still has limited scale. That means growth can exist, but current share looks too small to call it a Star. BioSentry needs heavier adoption and sales pull before it can move out of this low-share, high-uncertainty box.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized procedural product\u003c\/li\u003e\n\u003cli\u003eReal clinical need, narrow market\u003c\/li\u003e\n\u003cli\u003eGrowth possible, share still limited\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAngioDynamics’ Growth Bets Are Still Unproven\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAngioDynamics, Inc.’s Question Marks are still growth bets, not proven winners. In FY2025, the company reported about $286 million in net sales, while AlphaVac PE, Auryon CLI, NanoKnife pancreas, Solero, and BioSentry all needed more share and broader adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003cth\u003eBCG role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlphaVac PE\u003c\/td\u003e\n\u003ctd\u003eEarly share\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuryon CLI\u003c\/td\u003e\n\u003ctd\u003eAdoption building\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNanoKnife pancreas\u003c\/td\u003e\n\u003ctd\u003eLimited uptake\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSolero\u003c\/td\u003e\n\u003ctd\u003eShare still thin\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioSentry\u003c\/td\u003e\n\u003ctd\u003eNarrow market\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233983308041,"sku":"ango-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ango-bcg-matrix.webp?v=1785710891","url":"https:\/\/dcfanalyst.com\/products\/ango-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}